Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
Primary Purpose
Thoracic Diseases, Parathyroid Diseases
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
biotin
Sponsored by
About this trial
This is an interventional other trial for Thoracic Diseases focused on measuring biotin pharmacokinetic, biotinylated assay, hormone measurement, thyroid, parathyroid, prolactin
Eligibility Criteria
Inclusion Criteria:
Healthy adults
Exclusion Criteria:
- Pregnancy or lactation
- Known thyroid disease (goiter, abnormal thyroid state),
- Thyroid hormone treatment,
- Over the counter dietary/ nutritional supplement use currently or within the last 2 weeks (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium),
- Anticonvulsants,
- Night shift work, smokers, adults lacking capacity to consent for themselves
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Biotin arm
Arm Description
biotin 10 mg/day for 7 days
Outcomes
Primary Outcome Measures
Hormone measurements TSH, PTH, Total T4, free T4, total T3, free T3, prolactin
Hormone measurements using biotinylated assay conducted in certified labratory using the standard lab ranges for each test.
Secondary Outcome Measures
Full Information
NCT ID
NCT03034707
First Posted
January 17, 2017
Last Updated
April 17, 2019
Sponsor
University of Minnesota
Collaborators
Johns Hopkins University, Boston Medical Center, Children's Mercy Hospital Kansas City
1. Study Identification
Unique Protocol Identification Number
NCT03034707
Brief Title
Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
Official Title
Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
April 2016 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
December 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
Johns Hopkins University, Boston Medical Center, Children's Mercy Hospital Kansas City
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The B vitamin biotin is widely available as an over the counter supplement, often advertised and used to promote health of hair, skin and nails. Commercially available over the counter biotin supplements contain dose ranges up to 10 mg/day (ie 333 times higher than the recommended dietary allowance). The biotin molecule is also sometimes used as part of the lab technology to measure hormone and protein levels in the blood. It is possible that high doses of ingested biotin may interfere with accurate hormone or protein measurement using biotin related in vitro measurement systems. Such interference, if present, could lead to misdiagnosis. The study will analyze laboratory levels obtained with streptavidin-biotin assay systems while ingesting biotin in currently available high dose supplements. The data will be compared to measurements obtained prior to and one week after stopping the biotin supplement.
Detailed Description
Specimens will be collected by venipuncture at 3 time points, including baseline (time 0), after one week of biotin supplementation (time 1, day 7), and then one week later (time 2, day 14). The time 1 specimen will be drawn approximately 2 hours after the last ingested dose of biotin on day 7. Specimen collection will include three 10 ml red top (no gel) tubes at each timepoint.
Specimens will be separated for isolation of serum using routine methods of the clinical chemistry laboratory. Serum will be stored at -80 degrees C until batch measurements as described Measurements Biotin levels will be measured on each sample. Hormone measurements will be performed using specific commercially available streptavidin-biotin assays and using different analyzers as indicated below. Immunoassay methods, not employing biotin-streptavidin methodology, will be used for negative assay controls.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thoracic Diseases, Parathyroid Diseases
Keywords
biotin pharmacokinetic, biotinylated assay, hormone measurement, thyroid, parathyroid, prolactin
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Biotin arm
Arm Type
Experimental
Arm Description
biotin 10 mg/day for 7 days
Intervention Type
Dietary Supplement
Intervention Name(s)
biotin
Primary Outcome Measure Information:
Title
Hormone measurements TSH, PTH, Total T4, free T4, total T3, free T3, prolactin
Description
Hormone measurements using biotinylated assay conducted in certified labratory using the standard lab ranges for each test.
Time Frame
Change from baseline, at 7 days, at 14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy adults
Exclusion Criteria:
Pregnancy or lactation
Known thyroid disease (goiter, abnormal thyroid state),
Thyroid hormone treatment,
Over the counter dietary/ nutritional supplement use currently or within the last 2 weeks (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium),
Anticonvulsants,
Night shift work, smokers, adults lacking capacity to consent for themselves
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lynn A Burmeister, MD
Organizational Affiliation
Univ of Minnesota
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Angela Radulescu, MD
Organizational Affiliation
Univ of Minnesota
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
11800048
Citation
Fiume MZ; Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of biotin. Int J Toxicol. 2001;20 Suppl 4:1-12.
Results Reference
background
PubMed Identifier
19717659
Citation
Meany DL, Jan de Beur SM, Bill MJ, Sokoll LJ. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem. 2009 Sep;55(9):1737-9. doi: 10.1373/clinchem.2008.121921. No abstract available.
Results Reference
background
PubMed Identifier
22437752
Citation
Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology. 2012 Apr;44(3):278-80. doi: 10.1097/PAT.0b013e3283514002. No abstract available.
Results Reference
background
PubMed Identifier
23089740
Citation
Wijeratne NG, Doery JC, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology. 2012 Dec;44(7):674-5. doi: 10.1097/PAT.0b013e32835a3c17. No abstract available.
Results Reference
background
PubMed Identifier
28973622
Citation
Li D, Radulescu A, Shrestha RT, Root M, Karger AB, Killeen AA, Hodges JS, Fan SL, Ferguson A, Garg U, Sokoll LJ, Burmeister LA. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017 Sep 26;318(12):1150-1160. doi: 10.1001/jama.2017.13705.
Results Reference
derived
Learn more about this trial
Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
We'll reach out to this number within 24 hrs